The San Diego-based biotechnology firm Adventrx is capping off a turbulent past few years by changing its name to Mast Therapeutics and its stock ticker symbol from ANX to MSTX as of 11 March.
Even Adventrx's lead drug candidate – ANX-188 (purified poloxamer 188) for the treatment of vaso-occlusive crisis for patients with sickle cell disease – will be renamed MST-188
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?